{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T01:24:39Z","timestamp":1785201879774,"version":"3.55.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2012,5,24]],"date-time":"2012-05-24T00:00:00Z","timestamp":1337817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>For decades, somatostatin analogs (including octreotide and lanreotide) have been indicated for relief of the symptoms of flushing, diarrhea, and wheezing associated with secretory neuroendocrine tumors (NETs). Recently, it has been suggested that somatostatin analogs may provide direct and indirect antitumor effects in secretory and nonsecretory NETs in addition to symptom control in secretory NETs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>A systematic review of MEDLINE was conducted to identify studies that investigated the antitumor effects of octreotide or lanreotide for patients with NETs. Additional studies not published in the peer-reviewed literature were identified by searching online abstracts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>In all, 17 octreotide trials and 11 lanreotide trials that included antitumor effects were identified. Partial response rates were between 0% and 31%, and stable disease rates were between 15% and 89%. Octreotide was the only somatostatin analog for which results of a phase III, randomized, placebo-controlled clinical trial that investigated antitumor effects were published. After 6 months of treatment in this randomized phase III trial, stable disease was observed in 67% of patients (hazard ratio for time to disease progression: 0.34; 95% confidence interval: 0.20\u20130.59; p = .000072).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions.<\/jats:title>\n                  <jats:p>In addition to symptom control for NETs, the data support an antitumor effect of somatostatin analogs and suggest that they may slow tumor growth. Long-acting repeatable octreotide has been shown to have an antitumor effect in a randomized phase III trial in midgut NETs, whereas results are pending in a corresponding controlled trial with lanreotide for patients with intestinal and pancreatic primary NETs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0458","type":"journal-article","created":{"date-parts":[[2012,5,25]],"date-time":"2012-05-25T11:03:54Z","timestamp":1337943834000},"page":"747-755","source":"Crossref","is-referenced-by-count":77,"title":["Antitumor Effects of Somatostatin Analogs in Neuroendocrine Tumors"],"prefix":"10.1093","volume":"17","author":[{"given":"Lucas","family":"Sid\u00e9ris","sequence":"first","affiliation":[{"name":"a Department of Surgery, University of Montreal, Montr\u00e9al, Quebec, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dub\u00e9","sequence":"additional","affiliation":[{"name":"a Department of Surgery, University of Montreal, Montr\u00e9al, Quebec, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Rinke","sequence":"additional","affiliation":[{"name":"b Department of Gastroenterology and Endocrinology, University of Marburg, Marburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,5,24]]},"reference":[{"key":"2021122308222642200_B1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2010.33.2056","article-title":"Future directions in the treatment of neuroendocrine tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting","volume":"29","author":"Kulke","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308222642200_B2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/MPA.0b013e3181ebaffd","article-title":"NANETS consensus guidelines for the diagnosis of neuroendocrine tumor","volume":"39","author":"Vinik","year":"2010","journal-title":"Pancreas"},{"key":"2021122308222642200_B3","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308222642200_B4","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000085237","article-title":"Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours: A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)","volume":"80","author":"Plockinger","year":"2004","journal-title":"Neuroendocrinology"},{"key":"2021122308222642200_B5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/MPA.0b013e3181ebb168","article-title":"NANETS treatment guidelines: Well-differentiated neuroendocrine tumors of the stomach and pancreas","volume":"39","author":"Kulke","year":"2010","journal-title":"Pancreas"},{"key":"2021122308222642200_B6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1756-9966-29-19","article-title":"Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives","volume":"29","author":"Appetecchia","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"2021122308222642200_B7","volume-title":"Somatuline Autogel: Summary of product characteristics","year":"2002"},{"key":"2021122308222642200_B8","volume-title":"Sandostatin LAR depot (octreotide acetate for injectable suspension)","year":"2010"},{"key":"2021122308222642200_B9","doi-asserted-by":"crossref","first-page":"162","DOI":"10.12968\/hosp.2002.63.3.2062","article-title":"Somatuline autogel: An extended release lanreotide formulation","volume":"63","author":"Lightman","year":"2002","journal-title":"Hosp Med"},{"key":"2021122308222642200_B10","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122308222642200_B11","volume-title":"Somatuline LA: Summary of product characteristics","year":"2002"},{"key":"2021122308222642200_B12","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1677\/erc.0.0100451","article-title":"Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours","volume":"10","author":"De Herder","year":"2003","journal-title":"Endocr Relat Cancer"},{"key":"2021122308222642200_B13","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000289569","article-title":"VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K\/AKT\/mTOR pathway","volume":"91","author":"Villaume","year":"2010","journal-title":"Neuroendocrinology"},{"key":"2021122308222642200_B14","volume-title":"Sandostatin LAR: Summary of product characteristics","year":"2002"},{"key":"2021122308222642200_B15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome: Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"2021122308222642200_B16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122308222642200_B17","first-page":"134","article-title":"A 32-year-old man with copious, watery diarrhea","volume":"62","author":"Smith","year":"2001","journal-title":"N C Med J"},{"key":"2021122308222642200_B18","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0140-6736(85)92235-4","article-title":"Regression of metastatic vipoma with somatostatin analogue SMS 201-995","volume":"1","author":"Clements","year":"1985","journal-title":"Lancet"},{"key":"2021122308222642200_B19","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S0140-6736(86)90139-X","article-title":"Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995","volume":"2","author":"Shepherd","year":"1986","journal-title":"Lancet"},{"key":"2021122308222642200_B20","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122308222642200_B21","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.3748\/wjg.v16.i24.2963","article-title":"Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors","volume":"16","author":"Strosberg","year":"2010","journal-title":"World J Gastroenterol"},{"key":"2021122308222642200_B22","first-page":"23","article-title":"Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours","volume":"31","author":"Angeletti","year":"1999","journal-title":"Italian J Gastroenterol Hepatol"},{"key":"2021122308222642200_B23","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/02841869309083915","article-title":"Somatostatin analogue phase I trials in neuroendocrine neoplasms","volume":"32","author":"Anthony","year":"1993","journal-title":"Acta Oncol"},{"key":"2021122308222642200_B24","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0959-8049(01)00073-9","article-title":"Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours","volume":"37","author":"Aparicio","year":"2001","journal-title":"Eur J Cancer"},{"key":"2021122308222642200_B25","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122308222642200_B26","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/gut.38.3.430","article-title":"Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours","volume":"38","author":"Arnold","year":"1996","journal-title":"Gut"},{"key":"2021122308222642200_B27","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/annonc\/mdi258","article-title":"Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?","volume":"16","author":"Bajetta","year":"2005","journal-title":"Ann Oncol"},{"key":"2021122308222642200_B28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology Group","volume":"77","author":"Bartolomeo","year":"1996","journal-title":"Cancer"},{"key":"2021122308222642200_B29","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3109\/02841869109092409","article-title":"Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide","volume":"30","author":"Oberg","year":"1991","journal-title":"Acta Oncol"},{"key":"2021122308222642200_B30","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1008383132024","article-title":"Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide","volume":"11","author":"Ricci","year":"2000","journal-title":"Ann Oncol"},{"key":"2021122308222642200_B31","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"key":"2021122308222642200_B32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2036.2000.00738.x","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR","volume":"14","author":"Tomassetti","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"2021122308222642200_B33","doi-asserted-by":"crossref","first-page":"14S","DOI":"10.1007\/BF01536042","article-title":"Use of somatostatin analog in management of carcinoid syndrome","volume":"34","author":"Vinik","year":"1989","journal-title":"Dig Dis Sci"},{"key":"2021122308222642200_B34","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1677\/erc.1.01200","article-title":"Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma","volume":"13","author":"Butturini","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"2021122308222642200_B35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/annonc\/mdj113","article-title":"Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma","volume":"17","author":"Panzuto","year":"2006","journal-title":"Ann Oncol"},{"key":"2021122308222642200_B36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10195","article-title":"Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma","volume":"94","author":"Shojamanesh","year":"2001","journal-title":"Cancer"},{"key":"2021122308222642200_B37","volume-title":"Prospective randomized trial: Biotherapy versus chemotherapy in malignant nonfunctional neuroendocrine tumors of the pancreas and bronchial tract (ENET-1)","author":"Pavel","year":"2008"},{"key":"2021122308222642200_B38","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308222642200_B39","first-page":"4127","article-title":"High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors","volume":"29","author":"Chadha","year":"2009","journal-title":"Anticancer Res"},{"key":"2021122308222642200_B40","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.22272","article-title":"Lanreotide autogel every 6 weeks compared with lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: A phase III study","volume":"107","author":"Bajetta","year":"2006","journal-title":"Cancer"},{"key":"2021122308222642200_B41","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","article-title":"The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors","volume":"95","author":"Ducreux","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2021122308222642200_B42","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","article-title":"Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: The International Lanreotide and Interferon Alfa Study Group","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122308222642200_B43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000007693","article-title":"Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors","volume":"60","author":"Faiss","year":"1999","journal-title":"Digestion"},{"key":"2021122308222642200_B44","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","article-title":"Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors","volume":"23","author":"Ricci","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"2021122308222642200_B45","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1572-0241.1998.465_q.x","article-title":"Slow-release lanreotide treatment in endocrine gastrointestinal tumors","volume":"93","author":"Tomassetti","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"2021122308222642200_B46","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms","volume":"17","author":"Wymenga","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122308222642200_B47","doi-asserted-by":"crossref","first-page":"e14660","DOI":"10.1200\/jco.2011.29.15_suppl.e14660","article-title":"Evaluation of the efficacy and the safety of lanreotide autogel 120 mg on tumor growth stabilization in patients with progressive neuroendocrine tumors (NET) who are not eligible to surgery or chemotherapy","volume":"29","author":"Martin-Richard","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308222642200_B48","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/MPA.0b013e3181ec1261","article-title":"The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (NETS): Well-differentiated nets of the distal colon and rectum","volume":"39","author":"Anthony","year":"2010","journal-title":"Pancreas"},{"key":"2021122308222642200_B49","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","article-title":"The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: Well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum","volume":"39","author":"Boudreaux","year":"2010","journal-title":"Pancreas"},{"issue":"suppl 5","key":"2021122308222642200_B50","doi-asserted-by":"crossref","first-page":"v223","DOI":"10.1093\/annonc\/mdq192","article-title":"Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Oberg","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122308222642200_B51","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2021122308222642200_B52","first-page":"352","article-title":"Pasireotide strongly inhibits migration and proliferation of human micro- and macrovascular endothelial cells mainly via somatostatin receptor subtype 5 and FAK, ERK1\/2 and p38 pathways","volume":"147","author":"Pavel","year":"2006","journal-title":"Endocrinology"},{"key":"2021122308222642200_B53","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1677\/JME-08-0012","article-title":"Effects of somatostatin analog SOM230 on cell proliferation, apop-tosis, and catecholamine levels in cultured pheochromocytoma cells","volume":"40","author":"Pasquali","year":"2008","journal-title":"J Mol Endocrinol"},{"key":"2021122308222642200_B54","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT 2): A randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"key":"2021122308222642200_B55","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308222642200_B56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/13543784.16.2.219","article-title":"A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours","volume":"16","author":"Strosberg","year":"2007","journal-title":"Expert Opin Invest Drugs"},{"key":"2021122308222642200_B57","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1158\/0008-5472.CAN-09-2951","article-title":"The somatostatin analogue octreotide confers sensitivity to rapamycin treatment on pituitary tumor cells","volume":"70","author":"Cerovac","year":"2010","journal-title":"Cancer Res"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0458","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0458","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/6\/747\/41859553\/oncolo_17_6_747.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/6\/747\/41859553\/oncolo_17_6_747.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T21:33:41Z","timestamp":1640295221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/6\/747\/6400972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,24]]},"references-count":57,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2012,5,24]]},"published-print":{"date-parts":[[2012,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0458","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,6,1]]},"published":{"date-parts":[[2012,5,24]]}}}